Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.
Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Narita I, Kashihara N, Kadowaki T, Hase H, Akizawa T. Nangaku M, et al. Among authors: hase h. Nephrol Dial Transplant. 2023 May 4;38(5):1204-1216. doi: 10.1093/ndt/gfac242. Nephrol Dial Transplant. 2023. PMID: 36002026 Free PMC article. Clinical Trial.
A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study.
Akizawa T, Tsubakihara Y, Hirakata H, Watanabe Y, Hase H, Nishi S, Babazono T, Kumagai M, Katakura S, Uemura Y, Ohashi Y; JET-STREAM Study Group. Akizawa T, et al. Among authors: hase h. Clin Exp Nephrol. 2016 Dec;20(6):885-895. doi: 10.1007/s10157-015-1225-9. Epub 2016 Jan 16. Clin Exp Nephrol. 2016. PMID: 26779906 Free PMC article.
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Kato H, et al. Among authors: hase h. Clin Exp Nephrol. 2018 Feb;22(1):78-84. doi: 10.1007/s10157-017-1427-4. Epub 2017 Jun 28. Clin Exp Nephrol. 2018. PMID: 28660446 Free PMC article.
Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Kato H, et al. Among authors: hase h. Clin Exp Nephrol. 2018 Feb;22(1):85-86. doi: 10.1007/s10157-017-1461-2. Clin Exp Nephrol. 2018. PMID: 28875480 Free PMC article. No abstract available.
Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan.
Hayashi T, Kato H, Tanabe K, Nangaku M, Hirakata H, Wada T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Hayashi T, et al. Among authors: hase h. Clin Exp Nephrol. 2021 Feb;25(2):110-119. doi: 10.1007/s10157-020-01969-7. Epub 2020 Sep 19. Clin Exp Nephrol. 2021. PMID: 32949295 Free PMC article.
Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
Tsuruya K, Hayashi T, Yamamoto H, Hase H, Nishi S, Yamagata K, Nangaku M, Wada T, Uemura Y, Ohashi Y, Hirakata H; RADIANCE-CKD Study Investigators. Tsuruya K, et al. Among authors: hase h. Clin Exp Nephrol. 2021 May;25(5):456-466. doi: 10.1007/s10157-020-02005-4. Epub 2021 Jan 7. Clin Exp Nephrol. 2021. PMID: 33411115 Clinical Trial.
Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study.
Narita I, Hayashi T, Maruyama S, Masaki T, Nangaku M, Nishino T, Sato H, Sofue T, Wada T, Imai E, Iwasaki M, Mizuno K, Hase H, Kamouchi M, Yamamoto H, Kagimura T, Tanabe K, Kato H, Wada T, Usui T, Akizawa T, Hirakata H, Tsubakihara Y. Narita I, et al. Among authors: hase h. PLoS One. 2022 Nov 29;17(11):e0277921. doi: 10.1371/journal.pone.0277921. eCollection 2022. PLoS One. 2022. PMID: 36445882 Free PMC article.
209 results